CClinicalTrials.gg
Status unknownNCT04084379Updated Mar 1, 2023

Implementation Strategy of Bio-molecular Techniques for Early Diagnose of Congenital Syphilis and Chagas Diseases

An observational study in Chagas Disease and Syphilis, sponsored by Hospital de Niños R. Gutierrez de Buenos Aires. Status unknown at 1 site in Argentina. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2023-03-01.

Sponsored by Hospital de Niños R. Gutierrez de Buenos Aires · Observational

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
560
Ages
1 Day to 18 Years
Sex
All
01

Study summary

Chagas disease and syphilis are considered a mayor public health problem worldwide. Both pathologies affect socio-economic vulnerable population and they are both transmitted congenitally, causing an alarming increasing number of infected newborns. The current diagnostic methods for these diseases are based on serology follow-up until 8 to 10 months from birth, which considering the population usually involved and their scarce resources, usually translates in loosing continuity in their controls and follow-up.

Chagas prevalence in pregnant women is 4% with an incidence of Congenital Chagas disease of 1500 annual cases. From those, only 1 third are diagnosed. In the investigators and other authors experience, the detection of DNA of Trypanosoma cruzi by PCR shows an elevation of parasitemia at birth, with a peak at the first month of life.

Syphilis is a re-emergent pathology, preventable and curable when diagnose is achieved early at the beginning of pregnancy.. The cost-effectiveness of performing screening for this infection is widely demonstrated, preventing high morbi-mortality for children when applied to pregnant women.

For both syphilis and Chagas diagnosis, there are some studies comparing PCR follow-up with conventional serology, but none were validated and there is still need to bring more evidence in order to modify current practice. The investigators propose a sequential study of PCR for Tryipanosoma cruzi and Treponema pallidum from birth, believing this will increase sensitivity of congenital Chagas and syphilis diagnose and improve follow-up of these patients.

02

Conditions studied

  • Chagas Disease
  • Syphilis

Keywords

  • congenital chagas disease
  • congenital syphilis
  • Chagas PCR diagnose
  • Syphilis PCR diagnose
  • Children
03

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Population of this study are children born from mother positive for syphilis or Chagas diseases, with congenital infection suspected and children with acquired syphilis.

They will be recruited at five centers from different geographical areas of Argentina

Inclusion criteria

  • Child under 1 year of age, born from mother positive for syphilis not treated or inadequately treated during pregnancy
  • Patients with acquired syphilis
  • Child under 1 year of age, born from mother with positive serology test for Chagas

Exclusion criteria

Exclusion Criteria:

  • Patients who had received treatment for syphilis or Chagas previously
  • Patients who are not able to complete scheduled visits
  • Other diseases that could difficult implementation of this protocol or results interpretation.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
560 participants (estimated)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Implementation of Bio-molecular Techniques (PCR) for Early Diagnose of Congenital Syphilis and Chagas Diseases

    Evaluate PCR sensitivity, specificity, PPV and NPP in diagnose of congenital syphilis and congenital Chagas diseases and compare it with current methods. The investigators will measure PCR titles during one year in each patient, and then compare results with serologies, in order to assess if PCR positivization and negativization occurs earlier than current methods. This may allow physicians to shorten time required for follow-up in these patients.

    Time frame: 2 years

Secondary outcomes

  1. Implementation of Bio-molecular Techniques (PCR) as terapeutic response biomarker for Congenital Syphilis and Chagas Disease

    Investigators will evaluate the utility of PCR as an early biomarker of terapeutic response and compare it to serology for T.pallidum and T. cruzi during and after treatment. This could prevent unnecessary prolonged treatments, and could also allow early diagnose for treatment failures.

    Time frame: 2 years

  2. Identification of different genotypes of T.pallidum in samples to create a database of T.pallidum genotypes

    Identification of different genotypes of T.pallidum in samples taken from active skin lessions and blood samples, in order to create a data base of T.pallidum genotypes causing congenital syphilis and acquired syphilis

    Time frame: 2 years

06

Study locations

1 of 1 sites recruiting
  • Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires
    Buenos Aires, 1425, Argentina
    • Altcheh, Dr · Contact · jaltcheh@gmail.com · 54-11-4964-3093
    • Jaime Altcheh, Dr · Principal investigator
    Recruiting
07

Registry details

Key details

Study ID
NCT04084379
Lead sponsor
Hospital de Niños R. Gutierrez de Buenos Aires
Responsible party
Dr Jaime Altcheh (Principal Investigator, Hospital de Niños R. Gutierrez de Buenos Aires) — Principal investigator
First posted
Sep 10, 2019
Start date
Jul 1, 2019
Primary completion
Dec 30, 2023 (estimated)
Completion
Sep 1, 2024 (estimated)
Last update
Mar 1, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion